Ameriprise’s Abeona Therapeutics ABEO Stock Holding History

Ameriprise’s Portfolio ABEO Stock Details ABEO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-2,857	Closed	-$1.13M	–	3620
2017 Q4	$1.13M	Buy	+2,857	New	+$1.18M	﹤0.01%	2921

Other funds holding ABEO

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

KCM

Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Ameriprise's ABEO Position: Q1 2018 in Review

Ameriprise sold out of Abeona Therapeutics (ABEO) in Q1 2018, closing a stake of 2,857 shares — an estimated $1.13M sold.

Ameriprise first reported a position in ABEO in Q4 2017 and held it in 1 quarter. The position peaked at $1.13M in Q4 2017. 88 funds tracked by Wall St. Rank hold ABEO as of Q1 2018.

Ameriprise reported no remaining Abeona Therapeutics position as of Q1 2018 after selling out during the quarter.
Ameriprise sold 2,857 Abeona Therapeutics shares in Q1 2018, an estimated $1.13M.
Ameriprise first reported a position in Abeona Therapeutics in Q4 2017 and held it in 1 quarter.
Ameriprise's Abeona Therapeutics position peaked at $1.13M in Q4 2017.
88 funds tracked by Wall St. Rank held Abeona Therapeutics as of Q1 2018.

Based on Ameriprise's 13F filing for Q1 2018, filed 15 May 2018.